Vertex, GSK partner for Phase 2 all-oral hepatitis C study - Pharmaceutical Business

[INCIID News Feed]

Boston Globe
<img alt="" height="1" width="1" />
Vertex, GSK partner for Phase 2 all-oral hepatitis C study
Pharmaceutical Business Review
Vertex Pharmaceuticals and GlaxoSmithKline (GSK) have signed a non-exclusive agreement for Phase 2 all-oral hepatitis C study of VX-135 and GSK2336805. The companies will jointly fund the study that is expected to begin in 2013. Phase 2 ...
Mass. Movers Vertex up on hepatitis dealsBoston Globe
Vertex posts loss as hepatitis drug sales fallFinancial Express
Vertex Joins Glaxo, J&J in Testing Hepatitis C CombosBloomberg
RTT News -Boston Herald -Medical Marketing and Media
all 90 news articles &raquo;


More...